Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Price Target at $44.50

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been given an average rating of “Moderate Buy” by the twelve brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $44.4545.

A number of equities research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. The Goldman Sachs Group raised their target price on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Monday, March 2nd. Stifel Nicolaus restated a “buy” rating and issued a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. Barclays upped their price target on Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research report on Wednesday, December 17th. Finally, Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target for the company in a research note on Monday, March 23rd.

Institutional Trading of Celldex Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Aster Capital Management DIFC Ltd bought a new position in Celldex Therapeutics in the 3rd quarter worth approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in Celldex Therapeutics during the 3rd quarter valued at $42,000. Russell Investments Group Ltd. lifted its position in shares of Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Celldex Therapeutics in the third quarter worth $63,000. Finally, Strs Ohio bought a new position in shares of Celldex Therapeutics in the third quarter worth $75,000.

Celldex Therapeutics Stock Performance

CLDX opened at $30.30 on Monday. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $34.52. The firm has a 50-day moving average of $27.19 and a 200 day moving average of $26.51. The firm has a market cap of $2.02 billion, a P/E ratio of -7.79 and a beta of 1.17.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.22). Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%.The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $1.53 million. Equities research analysts predict that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.